FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Market Wrap: Morgan Stanley Issues Solid Q1 'Beat'; Prologis Enters Large Real Estate Deal; ForceField Energy Founder Exits
- IBM (IBM) Tops Q1 EPS Views
- After-Hours Stock Movers 04/20: (LRCX) (FTNT) (LJPC) Higher; (SANM) (UCTT) (PKG) Lower (more...)
- Prologis (PLD) to Acquire KTR Capital's Real Estate Portfolio in $5.9B Deal
- Rambus (RMBS) Tops Q1 EPS by 8c; Guides Q2 Revenue Below Expecations
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Peregrine Pharma (PPHM) Updates on Bavituximab Pilot Stude in Adenocarcinoma of the Lung
- St. Jude Medical (STJ) to Acquire Spinal Modulation in $175M + Milestones Deal
- Ligand Pharma (LGND) Announces Presentation of IRAK4 Inhibitor Compounds Data at AACR 2015
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!